News

Investing $100 can be a good amount to get started in stocks, especially if you're using a brokerage that charges low commission fees or none at all. And over time, you can steadily grow your

Investing $100 can be a good amount to get started in stocks, especially if you're using a brokerage that charges low commission fees or none at all. And over time, you can steadily grow your

Investors in Biogen (NASDAQ: BIIB) got some great news last week as the Food and Drug Administration (FDA) approved the company's Alzheimer's drug Leqembi. But despite the big win, the stock didn't

Investors in Biogen (NASDAQ: BIIB) got some great news last week as the Food and Drug Administration (FDA) approved the company's Alzheimer's drug Leqembi. But despite the big win, the stock didn't

Investors in Biogen (NASDAQ: BIIB) got some great news last week as the Food and Drug Administration (FDA) approved the company's Alzheimer's drug Leqembi. But despite the big win, the stock didn't

Make money. That's every investor's goal. How each person chooses to achieve that goal makes the difference in exactly how much money they make and how long it takes to make it.

Some stocks are

The S&P 500 is up 15% this year, and there are many stocks that have been performing much better than that. Shares of Hims & Hers Health (NYSE: HIMS) and Viking Therapeutics (NASDAQ: VKTX) have been

Vertex Pharmaceuticals' (NASDAQ: VRTX) stock has climbed nearly 20% so far this year, and for good reason. The biotech company completed a regulatory submission for what may become its next

Vertex Pharmaceuticals' (NASDAQ: VRTX) stock has climbed nearly 20% so far this year, and for good reason. The biotech company completed a regulatory submission for what may become its next

Vertex Pharmaceuticals' (NASDAQ: VRTX) stock has climbed nearly 20% so far this year, and for good reason. The biotech company completed a regulatory submission for what may become its next

Novavax (NASDAQ: NVAX) shares soared more than 30% in one trading session this week. That's a huge gain for any stock. But it's particularly impressive for Novavax. The biotech stock has been in the

Amid last year's difficult market, you may not have put all of your investable money to work -- in which case, you might have cash sitting on the sidelines. This would be the perfect time to deploy

Amid last year's difficult market, you may not have put all of your investable money to work -- in which case, you might have cash sitting on the sidelines. This would be the perfect time to deploy

Amid last year's difficult market, you may not have put all of your investable money to work -- in which case, you might have cash sitting on the sidelines. This would be the perfect time to deploy

Shares of Novavax (NASDAQ: NVAX) were up more than 24% as of 12:08 p.m. ET on Monday after the biotech company said Friday that Canada will pay $349.6 million for unused COVID-19 shots from the

Biogen (NASDAQ: BIIB) once stood out as one of the most successful biotech companies. It's portfolio of blockbuster multiple sclerosis drugs grew revenue into the billions of dollars. But as the

Biogen (NASDAQ: BIIB) once stood out as one of the most successful biotech companies. It's portfolio of blockbuster multiple sclerosis drugs grew revenue into the billions of dollars. But as the

Biogen (NASDAQ: BIIB) once stood out as one of the most successful biotech companies. It's portfolio of blockbuster multiple sclerosis drugs grew revenue into the billions of dollars. But as the

Some decisions are hard. Others, however, are so easy that they require much less thought.

Three Motley Fool contributors believe they've found stocks to buy that definitely fall into the latter

Shares of transplant diagnostics company CareDx (NASDAQ: CDNA) were up more than 20% as of 12:20 p.m. ET on Friday after a decision by the Centers for Medicare & Medicaid Services (CMS) that could